Alexander Christopher Jonathan van Akkooi
| Doctor Alexander Christopher Jonathan van Akkooi | |
|---|---|
| Born | Bridgeport, Connecticut |
| 🎓 Alma mater | Erasmus University Rotterdam |
| 💼 Occupation | |
| 🏢 Organization | Melanoma Institute Australia |
| 🌐 Website | melanoma.org.au/ |
Doctor Alexander van Akkooi is a surgical oncologist specialising in Melanoma and Sarcoma. [ResGate] He was born in Bridgeport, Connecticut, on 16 April 1981, and he lives in Sydney, Australia.[1]
Education and career
Akkooi achieved his doctorate cum laude in 2011 from Erasmus University Rotterdam. His dissertation was 'Sentinel Node (SN) Tumor Load Assessment in Melanoma: Dilemmas and Clinical Management'.[2] After graduating, he became a Resident Surgical Oncology at Erasmus MC before joining the Netherlands Cancer Institute at the Antoni van Leeuwenhoekziekenhuis hospital in January 2015. [ResGate] In 2022, Dr van Akkooi became the head of Melanoma surgery at the Melanoma Institute Australia (MIA). Simultaneously, he accepted an associate professorship at the University of Sydney.[1]
Research
In 2018, Akkooi was the Chairman of the European Organisation for Research and Treatment of Cancer (EORTC) Melanoma Group. Previously, he served as the Secretary from 2015 to 2018 and as the Early Career Investigator (ECI) member of the EORTC board from 2016 to 2018. [OncForum] Van Akkooi was the national coordinator of the EORTC 1325 and 1612 studies. Additionally, he was the principal investigator of the EORTC 1208 study, which commenced in 2009.[2] The EORTC 1208 study is a registry of melanoma patients with minimal sentinel node tumour burden.[3] [CancerResearchUKCambridgeInstitute] [EORTC]
Notable works
Dr van Akkooi has published one hundred and seventy peer-reviewed papers. [OncForum] His work includes neoadjuvant and adjuvant studies for stage III melanoma patients and locoregional therapies such as Isolated Limb Perfusion (ILP) and oncolytic virus programmes.
- Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (2018)[4]
- Dysfunctional CD8+ T cells form a proliferative, dynamically regulated compartment within human melanoma (2019)[5]
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma (2018)[6]
- Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative? (2006).[7]
- Melanoma (2018)- The Lancet[8]
References
- ↑ 1.0 1.1 "VAN AKKOOI, Dr Alexander C.J". Oncology Forum UK. Retrieved 2022-03-31. Unknown parameter
|url-status=ignored (help) - ↑ 2.0 2.1 "Alexander Christopher Jonathan van Akkooi". ResearchGate. Unknown parameter
|url-status=ignored (help) - ↑ "Minitub Registration Study (EORTC 1208)". Cancer Research UK. Retrieved 2022-03-31. Unknown parameter
|url-status=ignored (help) - ↑ Christian Blank, U (2018-10-08). "Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma". United States National Library of Medicine. 11: 1655–1661. doi:10.1038/s41591-018-0198-0 – via PubMed.
- ↑ Hanjie Li, H (2018-12-27). "Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma". United States National Library of Medicine. Retrieved 2022-03-31. Unknown parameter
|url-status=ignored (help) - ↑ Alexander Eggermont, A (2018-05-10). "Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma". The New England Journal of Medicine. Retrieved 2022-03-31. Unknown parameter
|url-status=ignored (help) - ↑ van Akkooi, Alexander (2006-09-12). "Clinical relevance of melanoma micrometastases ( <0.1 mm) in sentinel nodes: are these nodes to be considered negative?". Annals of Oncology. 10: 578–85 – via PubMed.
- ↑ van Akkooi, Alexander (2018-09-15). "Melanoma" (PDF). The Lancet. 10151: 971–984 – via The Lancet.
This article "Alexander van Akkooi" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Alexander van Akkooi. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
